Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions: Part 1: Supraventricular arrhythmias. A position statement of the Section of Sports Cardiology and Exercise from the European Association of Preventive Cardiology (EAPC) and the European Heart Rhythm Association (EHRA),both associations of the European Society of Cardiology
Restricted accessResearch articleFirst published online 2020
Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions: Part 1: Supraventricular arrhythmias. A position statement of the Section of Sports Cardiology and Exercise from the European Association of Preventive Cardiology (EAPC) and the European Heart Rhythm Association (EHRA),both associations of the European Society of Cardiology
Symptoms attributable to arrhythmias are frequently encountered in clinical practice. Cardiologists and sport physicians are required to identify high-risk individuals harbouring such conditions and provide appropriate advice regarding participation in regular exercise programmes and competitive sport. The three aspects that need to be considered are: (a) the risk of life-threatening arrhythmias by participating in sports; (b) control of symptoms due to arrhythmias that are not life-threatening but may hamper performance and/or reduce the quality of life; and (c) the impact of sports on the natural progression of the underlying arrhythmogenic condition. In many cases, there is no unequivocal answer to each aspect and therefore an open discussion with the athlete is necessary, in order to reach a balanced decision. In 2006 the Sports Cardiology and Exercise Section of the European Association of Preventive Cardiology published recommendations for participation in leisure-time physical activity and competitive sport in individuals with arrhythmias and potentially arrhythmogenic conditions. More than a decade on, these recommendations are partly obsolete given the evolving knowledge of the diagnosis, management and treatment of these conditions. The present document presents a combined effort by the Sports Cardiology and Exercise Section of the European Association of Preventive Cardiology and the European Heart Rhythm Association to offer a comprehensive overview of the most updated recommendations for practising cardiologists and sport physicians managing athletes with supraventricular arrhythmias, and provides pragmatic advice for safe participation in recreational physical activities, as well as competitive sport at amateur and professional level. A companion text on recommendations in athletes with ventricular arrhythmias, inherited arrhythmogenic conditions, pacemakers and implantable defibrillators is published as Part 2 in Europace.
HeidbuchelHPanhuyzen-GoedkoopNCorradoD, et al.;
Study Group on Sports Cardiology of the European Association for Cardiovascular Prevention and Rehabilitation. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil2006;
13: 475–484.
2.
HeidbuchelHCorradoDBiffiA, et al.;
Study Group on Sports Cardiology of the European Association for Cardiovascular Prevention and Rehabilitation. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: Ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil2006;
13: 676–686.
3.
PellicciaAFagardRBjornstadHH, et al.;
Experts who contributed to and revised parts of these recommendations: Study Group of Sports Cardiology of the Working Group of Cardiac R, Exercise P, Working Group of M, Pericardial Diseases of the European Society of C. Recommendations for competitive sports participation in athletes with cardiovascular disease: A consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J2005;
26: 1422–1445.
4.
HeidbuchelHArbeloED’AscenziF, et al.Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: Ventricular arrhythmias, channelopathies and implantable defibrillators. A position statement of the Section of Sports Cardiology and Exercise from the European Association of Preventive Cardiology (EAPC) and the European Heart Rhythm Association (EHRA), both associations of the European Society of Cardiology. Europace, In press.
5.
MaronBJ.Sudden death in young athletes. N Engl J Med2003;
349: 1064–1075.
6.
CorradoDBassoCRizzoliG, et al.Does sports activity enhance the risk of sudden death in adolescents and young adults?J Am Coll Cardiol2003;
42: 1959–1963.
7.
ThieneGNavaACorradoD, et al.Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med1988;
318: 129–133.
8.
CorradoDBassoCSchiavonM, et al.Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med1998;
339: 364–369.
9.
HeidbuchelHHoogsteenJFagardR, et al.High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. Eur Heart J2003;
24: 1473–1480.
10.
KwokCSAndersonSGMyintPK, et al.Physical activity and incidence of atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol2014;
177: 467–476.
11.
ElosuaRArquerAMontL, et al.Sport practice and the risk of lone atrial fibrillation: A case-control study. Int J Cardiol2006;
108: 332–337.
12.
MontLSambolaABrugadaJ, et al.Long-lasting sport practice and lone atrial fibrillation. Eur Heart J2002;
23: 477–482.
13.
HeidbuchelHAnneWWillemsR, et al.Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. Int J Cardiol2006;
107: 67–72.
14.
FurlanelloFBertoldiADallagoM, et al.Atrial fibrillation in elite athletes. J Cardiovasc Electrophysiol1998;
9: S63–S68.
15.
JamesCABhonsaleATichnellC, et al.Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol2013;
62: 1290–1297.
16.
KirchhofPFabritzLZwienerM, et al.Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation2006;
114: 1799–1806.
17.
La GercheARobberechtCKuiperiC, et al.Lower than expected desmosomal gene mutation prevalence in endurance athletes with complex ventricular arrhythmias of right ventricular origin. Heart2010;
96: 1268–1274.
18.
SawantACBhonsaleAte RieleAS, et al.Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc2014;
3: e001471.
19.
BenitoBGay-JordiGSerrano-MollarA, et al.Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation2011;
123: 13–22.
20.
HeidbuchelH.The athlete's heart is a proarrhythmic heart, and what that means for clinical decision making. Europace2018;
20: 1401–1411.
21.
CalkinsHSeifertMMoradyF.Clinical presentation and long-term follow-up of athletes with exercise-induced vasodepressor syncope. Am Heart J1995;
129: 1159–1164.
22.
PellicciaACaselliSSharmaS, et al.European Association of Preventive Cardiology (EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: Recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete's heart. Eur Heart J2018;
39: 1949–1969.
23.
MaronBJDoererJJHaasTS, et al.Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the United States, 1980–2006. Circulation2009;
119: 1085–1092.
24.
HarmonKGAsifIMMaleszewskiJJ, et al.Incidence, cause, and comparative frequency of sudden cardiac death in National Collegiate Athletic Association athletes: A decade in review. Circulation2015;
132: 10–19.
25.
FinocchiaroGPapadakisMRobertusJL, et al.Etiology of sudden death in sports: Insights from a United Kingdom regional registry. J Am Coll Cardiol2016;
67: 2108–2115.
26.
MittenMJZipesDPMaronBJ, et al.American Heart Association E, Arrhythmias Committee of Council on Clinical Cardiology CoCDiYCoC, Stroke Nursing CoFG, Translational B, American College of C. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 15: Legal aspects of medical eligibility and disqualification recommendations: A scientific statement from the American Heart Association and American College of Cardiology. Circulation2015;
132: e346–e349.
27.
MaronBJMittenMJQuandtEF, et al.Competitive athletes with cardiovascular disease–the case of Nicholas Knapp. N Engl J Med1998;
339: 1632–1635.
28.
PellicciaASolbergEEPapadakisM, et al.Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: Position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J2019;
40: 19–33.
29.
MittenMJ.Team physicians and competitive athletes: Allocating legal responsibility for athletic injuries. U Pitt L Rev1993;
55: 129.
30.
BjornstadHStorsteinLMeenHD, et al.Ambulatory electrocardiographic findings in top athletes, athletic students and control subjects. Cardiology1994;
84: 42–50.
31.
SharmaSWhyteGElliottP, et al.Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med1999;
33: 319–324.
32.
Jensen-UrstadKBouvierFSaltinB, et al.High prevalence of arrhythmias in elderly male athletes with a lifelong history of regular strenuous exercise. Heart1998;
79: 161–164.
33.
NorthcoteRJCanningGPBallantyneD.Electrocardiographic findings in male veteran endurance athletes. Br Heart J1989;
61: 155–160.
34.
BaldesbergerSBauersfeldUCandinasR, et al.Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J2008;
29: 71–78.
35.
BillmanGECagnoliKLCsepeT, et al.Exercise training-induced bradycardia: Evidence for enhanced parasympathetic regulation without changes in intrinsic sinoatrial node function. J Appl Physiol (1985)2015;
118: 1344–1355.
36.
MonfrediOLyashkovAEJohnsenAB, et al.Biophysical characterization of the underappreciated and important relationship between heart rate variability and heart rate. Hypertension2014;
64: 1334–1343.
37.
HerzigDAsatryanBBruggerN, et al.The association between endurance training and heart rate variability: The confounding role of heart rate. Front Physiol2018;
9: 756.
38.
SteinRMedeirosCMRositoGA, et al.Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes. J Am Coll Cardiol2002;
39: 1033–1038.
39.
D'SouzaAPearmanCMWangY, et al.Targeting miR-423-5p reverses exercise training-induced HCN4 channel remodeling and sinus bradycardia. Circ Res2017;
121: 1058–1068.
40.
BrignoleMAuricchioABaron-EsquiviasG, et al.2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on Cardiac Pacing and Resynchronization Therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).Eur Heart J2013;
34: 2281–2329.
41.
EctorHBourgoisJVerlindenM, et al.Bradycardia, ventricular pauses, syncope, and sports. Lancet1984;
2: 591–594.
42.
ZeppilliPFeniciRSassaraM, et al.Wenckebach second-degree A-V block in top-ranking athletes: An old problem revisited. Am Heart J1980;
100: 281–294.
43.
GuaschEMontL.Diagnosis, pathophysiology, and management of exercise-induced arrhythmias. Nat Rev Cardiol2017;
14: 88–101.
44.
ZehenderMMeinertzTKeulJ, et al.ECG variants and cardiac arrhythmias in athletes: Clinical relevance and prognostic importance. Am Heart J1990;
119: 1378–1391.
45.
BettiniRFurlanelloFVecchietL, et al. [
Cardiac rhythm in athletes: A Holter study of top level and ex-professional football players]. G Ital Cardiol1990;
20: 810–818.
46.
DoutreleauSPisteaCLonsdorferE, et al.Exercise-induced second-degree atrioventricular block in endurance athletes. Med Sci Sports Exerc2013;
45: 411–414.
VidalAAgorrodyVAbreuR, et al.Vagal third-degree atrioventricular block in a highly trained endurance athlete. Europace2017;
19: 1863.
49.
TalanDABauernfeindRAAshleyWW, et al.Twenty-four hour continuous ECG recordings in long-distance runners. Chest1982;
82: 19–24.
50.
ConenDAdamMRocheF, et al.Premature atrial contractions in the general population: Frequency and risk factors. Circulation2012;
126: 2302–2308.
51.
WilhelmMRotenLTannerH, et al.Atrial remodeling, autonomic tone, and lifetime training hours in nonelite athletes. Am J Cardiol2011;
108: 580–585.
52.
BiniciZIntzilakisTNielsenOW, et al.Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation2010;
121: 1904–1911.
53.
OrejarenaLAVidailletHJrDeStefanoF, et al.Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol1998;
31: 150–157.
54.
MiljoenHEctorJGarwegC, et al.Differential presentation of atrioventricular nodal re-entrant tachycardia in athletes and non-athletes. Europace2019;
21: 944–949.
55.
BrugadaJKatritsisDGArbeloE, et al..
2019 ESC guidelines for the management of patients with supraventricular tachycardia: The Task Force for the Management of Patients with Supraventricular Tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41: 655–720.
56.
MediCKalmanJMHaqqaniH, et al.Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: Long-term outcome after catheter ablation. J Am Coll Cardiol2009;
53: 1791–1797.
57.
BrachmannJLewalterTKuckKH, et al.Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: Insights from the German Ablation Registry. Eur Heart J2017;
38: 1317–1326.
58.
CalkinsHYongPMillerJM, et al.Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: Final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation1999;
99: 262–270.
59.
TimmermansCSmeetsJLRodriguezLM, et al.Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol1995;
76: 492–494.
60.
KleinGJBashoreTMSellersTD, et al.Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med1979;
301: 1080–1085.
61.
CohenMITriedmanJKCannonBC, et al.PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm2012;
9: 1006–1024.
62.
FriedmanRAWalshEPSilkaMJ, et al.NASPE Expert Consensus Conference: Radiofrequency catheter ablation in children with and without congenital heart disease. Report of the writing committee. North American Society of Pacing and Electrophysiology. Pacing Clin Electrophysiol2002;
25: 1000–1017.
63.
SharmaADYeeRGuiraudonG, et al.Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome. J Am Coll Cardiol1987;
10: 373–381.
64.
JanuaryCTWannLSAlpertJS, et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation2014;
130: e199–e267.
65.
KirchhofPBenussiSKotechaD, et al.2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J2016;
37: 2893–2962.
66.
Blomstrom-LundqvistCScheinmanMMAliotEM, et al.ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias–executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol2003;
42: 1493–1531.
67.
GaitaFGiustettoCRiccardiR, et al.Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death. Am J Cardiol1989;
64: 487–490.
68.
PapponeCSantinelliVRosanioS, et al.Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern: Results from a large prospective long-term follow-up study. J Am Coll Cardiol2003;
41: 239–244.
69.
WellensHJRodriguezLMTimmermansC, et al.The asymptomatic patient with the Wolff-Parkinson-White electrocardiogram. Pacing Clin Electrophysiol1997;
20: 2082–2086.
70.
PageRLJoglarJACaldwellMA, et al.2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm2016;
13: e136–e221.
71.
MungerTMPackerDLHammillSC, et al.A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953–1989. Circulation1993;
87: 866–873.
72.
VidailletHJJrPressleyJCHenkeE, et al.Familial occurrence of accessory atrioventricular pathways (preexcitation syndrome). N Engl J Med1987;
317: 65–69.
73.
DealBJKeaneJFGillettePC, et al.Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: Management and follow-up. J Am Coll Cardiol1985;
5: 130–135.
74.
GoudevenosJAKatsourasCSGraekasG, et al.Ventricular pre-excitation in the general population: A study on the mode of presentation and clinical course. Heart2000;
83: 29–34.
75.
BecquartJVaksmannGBecquartV, et al.[Prognosis of Wolff-Parkinson-White syndrome in infants. Apropos of 31 cases].Arch Mal Coeur Vaiss1988;
81: 695–700.
76.
SoriaRGuizeLChretienJM, et al.[The natural history of 270 cases of Wolff-Parkinson-White syndrome in a survey of the general population].Arch Mal Coeur Vaiss1989;
82: 331–336.
77.
MilsteinSSharmaADKleinGJ.Electrophysiologic profile of asymptomatic Wolff-Parkinson-White pattern. Am J Cardiol1986;
57: 1097–1100.
78.
DelisePD'EsteDBonsoA, et al. [
Different degrees of risk of high-frequency atrial fibrillation in symptomatic and asymptomatic WPW syndrome. Electrophysiologic evaluation]. G Ital Cardiol1987;
17: 127–133.
79.
ObeyesekereMNLeong-SitPMasselD, et al.Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: A meta-analysis. Circulation2012;
125: 2308–2315.
80.
FukataniMTanigawaMMoriM, et al.Prediction of a fatal atrial fibrillation in patients with asymptomatic Wolff-Parkinson-White pattern. Jpn Circ J1990;
54: 1331–1339.
81.
PietersenAHAndersenEDSandoeE.Atrial fibrillation in the Wolff-Parkinson-White syndrome. Am J Cardiol1992;
70: 38A–43A.
82.
SantinelliVRadinovicAMangusoF, et al.Asymptomatic ventricular preexcitation: A long-term prospective follow-up study of 293 adult patients. Circ Arrhythm Electrophysiol2009;
2: 102–107.
83.
DelisePSciarraL.Asymptomatic Wolff-Parkinson-White: What to do. Extensive ablation or not?J Cardiovasc Med (Hagerstown)2007;
8: 668–674.
84.
BassoCCorradoDRossiL, et al.Ventricular preexcitation in children and young adults: Atrial myocarditis as a possible trigger of sudden death. Circulation2001;
103: 269–275.
85.
BrombergBILindsayBDCainME, et al.Impact of clinical history and electrophysiologic characterization of accessory pathways on management strategies to reduce sudden death among children with Wolff-Parkinson-White syndrome. J Am Coll Cardiol1996;
27: 690–695.
86.
MahDYSherwinEDAlexanderME, et al.The electrophysiological characteristics of accessory pathways in pediatric patients with intermittent preexcitation. Pacing Clin Electrophysiol2013;
36: 1117–1122.
87.
KigerMEMcCantaACTongS, et al.Intermittent versus persistent Wolff-Parkinson-White syndrome in children: Electrophysiologic properties and clinical outcomes. Pacing Clin Electrophysiol2016;
39: 14–20.
88.
PapponeCMangusoFSantinelliR, et al.Radiofrequency ablation in children with asymptomatic Wolff-Parkinson-White syndrome. N Engl J Med2004;
351: 1197–1205.
89.
EtheridgeSPEscuderoCABlaufoxAD, et al.Life-threatening event risk in children with Wolff-Parkinson-White Syndrome: A multicenter international study. JACC Clin Electrophysiol2018;
4: 433–444.
90.
MozaffarianDFurbergCDPsatyBM, et al.Physical activity and incidence of atrial fibrillation in older adults: The Cardiovascular Health Study. Circulation2008;
118: 800–807.
91.
DuXDongJMaC.Is atrial fibrillation a preventable disease?J Am Coll Cardiol2017;
69: 1968–1982.
92.
PathakRKElliottAMiddeldorpME, et al.Impact of cardiorespiratory fitness on arrhythmia recurrence in obese individuals with atrial fibrillation: The CARDIO-FIT study. J Am Coll Cardiol2015;
66: 985–996.
93.
RienstraMHobbeltAHAlingsM, et al.Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: Results of the RACE 3 trial. Eur Heart J2018;
39: 2987–2996.
94.
ElliottADMaatmanBEmeryMS, et al.The role of exercise in atrial fibrillation prevention and promotion: Finding optimal ranges for health. Heart Rhythm2017;
14: 1713–1720.
95.
AizerAGazianoJMCookNR, et al.Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol2009;
103: 1572–1577.
96.
MorsethBGraff-IversenSJacobsenBK, et al.Physical activity, resting heart rate, and atrial fibrillation: The Tromso study. Eur Heart J2016;
37: 2307–2313.
97.
AndersenKFarahmandBAhlbomA, et al.Risk of arrhythmias in 52 755 long-distance cross-country skiers: A cohort study. Eur Heart J2013;
34: 3624–3631.
98.
GuaschEBenitoBQiX, et al.Atrial fibrillation promotion by endurance exercise: Demonstration and mechanistic exploration in an animal model. J Am Coll Cardiol2013;
62: 68–77.
99.
BoraitaASantos-LozanoAHerasME, et al.Incidence of atrial fibrillation in elite athletes. JAMA Cardiol2018;
3: 1200–1205.
100.
PeritzDKaurGWasmundS, et al.Endurance training is associated with increased left atrial fibrosis. Eur Heart J2018;
39: 973–974.
101.
Aschar-SobbiRIzaddoustdarFKorogyiAS, et al.Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNF alpha. Nat Commun2015;
6: 6018.
102.
SullivanMLMartinezCMGallagherEJ.Atrial fibrillation and anabolic steroids. J Emerg Med1999;
17: 851–857.
103.
LauDHStilesMKJohnB, et al.Atrial fibrillation and anabolic steroid abuse. Int J Cardiol2007;
117: e86–e87.
104.
FurlanelloFSerdozLVCappatoR, et al.Illicit drugs and cardiac arrhythmias in athletes. Eur J Cardiovasc Prev Rehabil2007;
14: 487–494.
105.
Brembilla-PerrotBHouriezPBeurrierD, et al.Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias. Int J Cardiol2001;
80: 7–15.
106.
KawabataMHiraoKHorikawaT, et al.Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. J Electrocardiol2001;
34: 65–72.
107.
NabarARodriguezLMTimmermansC, et al.Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: Observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation. Circulation1999;
99: 1441–1445.
108.
ReithmannCDorwarthUDugasM, et al.Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter. Eur Heart J2003;
24: 1264–1272.
109.
AlboniPBottoGLBaldiN, et al.Outpatient treatment of recent-onset atrial fibrillation with the ‘pill-in-the-pocket’ approach. N Engl J Med2004;
351: 2384–2391.
110.
CalkinsHHindricksGCappatoR, et al.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm2017;
14: e275–e444.
111.
CalvoNMontLTamboreroD, et al.Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace2010;
12: 30–36.
112.
FurlanelloFLupoPPittalisM, et al.Radiofrequency catheter ablation of atrial fibrillation in athletes referred for disabling symptoms preventing usual training schedule and sport competition. J Cardiovasc Electrophysiol2008;
19: 457–462.
113.
KoopmanPNuyensDGarwegC, et al.Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. Europace2011;
13: 1386–1393.
114.
SteffelJVerhammePPotparaTS, et al.The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Eur Heart J2018;
39: 1330–1393.
115.
PellicciaAMaronBJDi PaoloFM, et al.Prevalence and clinical significance of left atrial remodeling in competitive athletes. J Am Coll Cardiol2005;
46: 690–696.
116.
D'AscenziFAnselmiFFocardiM, et al.Atrial enlargement in the athlete's heart: Assessment of atrial function may help distinguish adaptive from pathologic remodeling. J Am Soc Echocardiogr2018;
31: 148–157.
117.
CalvoNBrugadaJSitgesM, et al.Atrial fibrillation and atrial flutter in athletes. Br J Sports Med2012;
46: i37–i43.
118.
HoogsteenJSchepGVan HemelNM, et al.Paroxysmal atrial fibrillation in male endurance athletes. A 9-year follow up. Europace2004;
6: 222–228.
119.
SchmiederSNdrepepaGDongJ, et al.Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J2003;
24: 956–962.
120.
AnneWWillemsRVan der MerweN, et al.Atrial fibrillation after radiofrequency ablation of atrial flutter: Preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart2004;
90: 1025–1030.
121.
PerezFJSchubertCMParvezB, et al.Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: A meta-analysis. Circ Arrhythm Electrophysiol2009;
2: 393–401.
